Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2022-07-21 00:00:00 ET · period of report 2022-07-19 · accession 0001714899-22-000107 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-07-21 | 2022-07-19 | DNLI | Krognes Steve E. | Dir | M - OptEx | $0.68 | +62.5K | 151.7K | +70% | +$42.5K |
| D | 2022-07-21 | 2022-07-19 | DNLI | Krognes Steve E. | Dir | M - OptEx | $0.00 | -62.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-07-19 | M | A | 62,500 | $0.68 | 151,721 | D | — | — | (F1) Includes 56,322 restricted stock units. |
| 2 | Derivative | Stock Option (right to buy) | 2022-07-19 | M | D | 62,500 | $0.00 | 0 | D | $0.68 · 2022-07-19 to 2022-08-01 | 62,500 Common Stock | (F3) 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vested monthly thereafter. |